MX2020002896A - Proceso para formulacion farmaceutica liofilizada de una proteina terapeutica. - Google Patents
Proceso para formulacion farmaceutica liofilizada de una proteina terapeutica.Info
- Publication number
- MX2020002896A MX2020002896A MX2020002896A MX2020002896A MX2020002896A MX 2020002896 A MX2020002896 A MX 2020002896A MX 2020002896 A MX2020002896 A MX 2020002896A MX 2020002896 A MX2020002896 A MX 2020002896A MX 2020002896 A MX2020002896 A MX 2020002896A
- Authority
- MX
- Mexico
- Prior art keywords
- formulation
- protein
- therapeutic protein
- lyophilized pharmaceutical
- pharmaceutical formulation
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 8
- 108090000623 proteins and genes Proteins 0.000 title abstract 8
- 230000001225 therapeutic effect Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 5
- 239000013020 final formulation Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/196—Thrombopoietin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/524—Thrombopoietin, i.e. C-MPL ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a un proceso para preparar una formulación farmacéutica liofilizada de una proteína terapéutica, que comprende (a) proporcionar una formulación de una cantidad volumétrica de la proteína terapéutica, (b) medir la concentración de la proteína terapéutica en dicha formulación volumétrica, (c) ajustar el peso de la carga de la proteína en dicha formulación volumétrica para conseguir una dosis fija de la proteína, y (d) liofilizar la formulación ajustada al peso de la carga de la proteína para conseguir una formulación final en un recipiente, donde la concentración del producto tras la reconstitución con un volumen fijo está comprendida en un intervalo de aceptación predeterminado. El proceso es particularmente adecuado para formulaciones con concentraciones de proteínas bajas (por ejemplo, de 0.05 mg/mL a 20 mg/mL).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762559420P | 2017-09-15 | 2017-09-15 | |
PCT/US2018/050305 WO2019055357A1 (en) | 2017-09-15 | 2018-09-10 | METHOD FOR THE LYOPHILIZED PHARMACEUTICAL FORMULATION OF A THERAPEUTIC PROTEIN |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020002896A true MX2020002896A (es) | 2020-07-22 |
Family
ID=63686145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020002896A MX2020002896A (es) | 2017-09-15 | 2018-09-10 | Proceso para formulacion farmaceutica liofilizada de una proteina terapeutica. |
Country Status (22)
Country | Link |
---|---|
US (2) | US20190083402A1 (es) |
EP (1) | EP3681483B1 (es) |
JP (2) | JP2020534255A (es) |
KR (1) | KR20200054251A (es) |
CN (1) | CN111148510A (es) |
AU (1) | AU2018334502A1 (es) |
BR (1) | BR112020004902A2 (es) |
CA (1) | CA3072600A1 (es) |
CL (1) | CL2020000625A1 (es) |
DK (1) | DK3681483T3 (es) |
EA (1) | EA202090731A1 (es) |
ES (1) | ES2925232T3 (es) |
HU (1) | HUE059339T2 (es) |
IL (2) | IL272513B2 (es) |
LT (1) | LT3681483T (es) |
MA (1) | MA50239A (es) |
MX (1) | MX2020002896A (es) |
PL (1) | PL3681483T3 (es) |
PT (1) | PT3681483T (es) |
SG (1) | SG11202001449VA (es) |
SI (1) | SI3681483T1 (es) |
WO (1) | WO2019055357A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111595658B (zh) * | 2020-06-06 | 2023-11-14 | 宾傲 | 一种提取细胞中蛋白的裂解液及其制备方法 |
US11583521B2 (en) * | 2020-07-01 | 2023-02-21 | Jubilant Pharma Holdings Inc. | Long-acting injection dosage form of beta 3 adrenoreceptor agonists |
CN114681592A (zh) * | 2020-12-31 | 2022-07-01 | 天境生物科技(杭州)有限公司 | 包含可溶性gp130二聚体的制剂和使用方法 |
CN113087782B (zh) * | 2021-04-09 | 2021-12-14 | 北京美联泰科生物技术有限公司 | 一种中枢神经特异性蛋白的冻干方法 |
CN117241787A (zh) * | 2021-06-01 | 2023-12-15 | 安进公司 | 制备冻干蛋白配制品的加速方法 |
WO2023180525A1 (en) * | 2022-03-24 | 2023-09-28 | Richter Gedeon Nyrt. | Method for the manufacture of biopharmaceuticals |
CN115932239B (zh) * | 2022-12-22 | 2024-02-20 | 广州市进德生物科技有限公司 | 一种氧化低密度脂蛋白保护剂、测定氧化低密度脂蛋白的检测试剂盒及其应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0623679B1 (en) | 1987-05-21 | 2003-06-25 | Micromet AG | Targeted multifunctional proteins |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
BRPI9909860B8 (pt) | 1998-04-21 | 2021-05-25 | Amgen Res Munich Gmbh | polipeptídeo multifuncional de cadeia simples, polinucleotídeo, vetor, célula procariótica, de levedura ou unicelular, composição, usos de polipeptídeo e polinucleotídeo e métodos para preparo do referido polipeptídeo e para identificação de ativadores ou inibidores de ativação ou estimulação das células t |
MXPA04004459A (es) * | 2001-11-09 | 2005-05-16 | Johnson & Johnson | Composiciones liofilizadas de anticuerpo monoclonal. |
WO2004039337A2 (en) | 2002-10-31 | 2004-05-13 | Protein Design Labs, Inc. | Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization |
EA012801B1 (ru) | 2005-06-14 | 2009-12-30 | Эмджен Инк. | Самобуферирующиеся композиции белков |
WO2007074880A1 (ja) * | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
EP2144624A1 (en) | 2007-05-15 | 2010-01-20 | Stryker Corporation | Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof |
US9345661B2 (en) * | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
EP2640750A1 (en) | 2010-11-16 | 2013-09-25 | Boehringer Ingelheim International GmbH | Agents and methods for treating diseases that correlate with bcma expression |
AR089434A1 (es) * | 2011-12-23 | 2014-08-20 | Genentech Inc | Procedimiento para preparar formulaciones con alta concentracion de proteinas |
US9872906B2 (en) * | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
WO2014179648A2 (en) * | 2013-05-02 | 2014-11-06 | The University Of North Carolina At Chapel Hill | Direct anti-markovnikov addition of acids to alkenes |
CA2943919A1 (en) * | 2014-03-29 | 2015-10-08 | Intas Pharmaceuticals Ltd. | Lyophilized pharmaceutical composition of fc-peptide fusion protein |
JOP20170017B1 (ar) | 2016-01-25 | 2021-08-17 | Amgen Res Munich Gmbh | تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص |
-
2018
- 2018-09-10 MA MA050239A patent/MA50239A/fr unknown
- 2018-09-10 CA CA3072600A patent/CA3072600A1/en active Pending
- 2018-09-10 PT PT187791678T patent/PT3681483T/pt unknown
- 2018-09-10 ES ES18779167T patent/ES2925232T3/es active Active
- 2018-09-10 KR KR1020207010535A patent/KR20200054251A/ko not_active Application Discontinuation
- 2018-09-10 MX MX2020002896A patent/MX2020002896A/es unknown
- 2018-09-10 EA EA202090731A patent/EA202090731A1/ru unknown
- 2018-09-10 US US16/127,123 patent/US20190083402A1/en not_active Abandoned
- 2018-09-10 PL PL18779167.8T patent/PL3681483T3/pl unknown
- 2018-09-10 JP JP2020508006A patent/JP2020534255A/ja active Pending
- 2018-09-10 IL IL272513A patent/IL272513B2/en unknown
- 2018-09-10 AU AU2018334502A patent/AU2018334502A1/en active Pending
- 2018-09-10 DK DK18779167.8T patent/DK3681483T3/da active
- 2018-09-10 CN CN201880058941.7A patent/CN111148510A/zh active Pending
- 2018-09-10 EP EP18779167.8A patent/EP3681483B1/en active Active
- 2018-09-10 LT LTEPPCT/US2018/050305T patent/LT3681483T/lt unknown
- 2018-09-10 IL IL297824A patent/IL297824A/en unknown
- 2018-09-10 BR BR112020004902-6A patent/BR112020004902A2/pt unknown
- 2018-09-10 SI SI201830739T patent/SI3681483T1/sl unknown
- 2018-09-10 WO PCT/US2018/050305 patent/WO2019055357A1/en unknown
- 2018-09-10 SG SG11202001449VA patent/SG11202001449VA/en unknown
- 2018-09-10 US US16/652,667 patent/US20210369616A1/en active Pending
- 2018-09-10 HU HUE18779167A patent/HUE059339T2/hu unknown
-
2020
- 2020-03-11 CL CL2020000625A patent/CL2020000625A1/es unknown
-
2023
- 2023-07-06 JP JP2023111202A patent/JP2023126930A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SI3681483T1 (sl) | 2022-10-28 |
DK3681483T3 (da) | 2022-08-29 |
IL272513B (en) | 2022-12-01 |
PL3681483T3 (pl) | 2022-09-26 |
CL2020000625A1 (es) | 2020-08-21 |
KR20200054251A (ko) | 2020-05-19 |
IL272513B2 (en) | 2023-04-01 |
JP2023126930A (ja) | 2023-09-12 |
PT3681483T (pt) | 2022-08-22 |
EP3681483A1 (en) | 2020-07-22 |
AU2018334502A1 (en) | 2020-03-12 |
US20190083402A1 (en) | 2019-03-21 |
ES2925232T3 (es) | 2022-10-14 |
EA202090731A1 (ru) | 2020-06-11 |
CA3072600A1 (en) | 2019-03-21 |
US20210369616A1 (en) | 2021-12-02 |
BR112020004902A2 (pt) | 2020-09-15 |
HUE059339T2 (hu) | 2022-11-28 |
IL272513A (en) | 2020-03-31 |
LT3681483T (lt) | 2022-09-12 |
JP2020534255A (ja) | 2020-11-26 |
CN111148510A (zh) | 2020-05-12 |
WO2019055357A1 (en) | 2019-03-21 |
EP3681483B1 (en) | 2022-05-18 |
IL297824A (en) | 2023-01-01 |
SG11202001449VA (en) | 2020-03-30 |
MA50239A (fr) | 2020-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020002896A (es) | Proceso para formulacion farmaceutica liofilizada de una proteina terapeutica. | |
MX2017005874A (es) | Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf. | |
AU2016204371A1 (en) | Lyophilised and aqueous anti-CD40 antibody formulations | |
MY172735A (en) | Formulation for anti-?4?7 antibody | |
MY188749A (en) | Compositions comprising a combination of nivolumab and ipilimumab | |
MX2010002409A (es) | Composiciones y metodos para la distribucion de farmacos escasamente solubles. | |
MY188825A (en) | High-concentration monoclonal antibody formulations | |
MX2012010114A (es) | Formulaciones concentradas de proteina y usos de las mismas. | |
CY1108732T1 (el) | Καψουλα δυο τμηματων με προκαταρκτικο κλεισιμο για την τοποθετηση φαρμακευτικων παρασκευασματων για συσκευες εισπνοης κονεως | |
NZ702342A (en) | Pharmaceutical formulation | |
MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
MX2021005085A (es) | Formulacion de anticuerpo. | |
WO2019011955A3 (de) | Solubilisat mit curcumin und optional zumindest einem weiteren wirkstoff | |
Quanjun et al. | Parthenolide from Parthenium integrifolium reduces tumor burden and alleviate cachexia symptoms in the murine CT-26 model of colorectal carcinoma | |
PH12016500414B1 (en) | Solid preparation containing choline alfoscerate and method for preparing same | |
JOP20210229A1 (ar) | صيغة جسم مضاد علاجي | |
MX2017005163A (es) | Composiciones de liberación prolongada de onapristona y métodos. | |
MX2017013633A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas. | |
GB201122430D0 (en) | Reconstitution method for high concentration dry protein formulation | |
Rangasamy et al. | Formulation development and evaluation of voriconazole sustained release tablets | |
MX2017013643A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz. | |
MX2020005921A (es) | Formulaciones y metodos para el suministro vaginal de antiprogestinas. | |
CY1120282T1 (el) | Φαρμακευτικη συνθεση κιτρικης σιλδεναφιλης με την μορφη ενος εναιωρηματος για εκ του στοματος χρηση | |
EA202090568A1 (ru) | Составы копанлисиба | |
MX2017013634A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo. |